Enfortumab Vedotin & Bladder Cancer: Thomas Powles, MD ESMO 2023

An exclusive interview took place with Dr. Thomas Powles, MD. He discussed the Enfortumab Vedotin and Pembrolizumab combination, emphasizing their significant results in treating bladder cancer. The focus was on exploring key questions and examining the potential impact of this transformative therapy on patient care.


By: Thomas Powles, MD

Date: October 25, 2023

An exclusive interview occurred with Dr. Thomas Powles, MD, the lead investigator of the EV-302 phase 3 trial, where the discussion revolved around the Enfortumab Vedotin and Pembrolizumab combination and its potential impact on bladder cancer treatment.

During the interview, Dr. Powles detailed how the Enfortumab Vedotin-Pembrolizumab combination displayed a 53% reduction in the risk of death in comparison to conventional chemotherapy for bladder cancer patients.

The conversation explored the factors contributing to the extended median overall survival of 31.5 months for patients on the combination regimen, a significant improvement over the 16.1 months observed with chemotherapy alone.

Dr. Powles discussed the implications of the combination's success in progression-free survival (PFS), which showcased a 55% reduction in risk and its influence on treatment options for bladder cancer patients.

The interview delved into the safety considerations and adverse events observed with the Enfortumab Vedotin-Pembrolizumab combination, particularly focusing on its safety profile in contrast to chemotherapy.

Dr. Powles elaborated on the side effects of peripheral neuropathy in patients taking Enfortumab Vedotin and how this concern was addressed in the study.

The discussion explored the implications of the 67.7% objective response rate achieved by the combination and its potential effectiveness in treatment.

Dr. Powles talked about how including cisplatin-eligible patients in the combination's label significantly broadens the potential patient pool for Enfortumab Vedotin, offering hope to a wider range of patients.

In the context of the study, Dr. Powles evaluated the transformative potential of the Pembrolizumab-Enfortumab Vedotin combination, identifying specific areas that may require further evaluation for its effectiveness.

This detailed interview offered insights into the groundbreaking results of the EV-302 trial and the promise of the Enfortumab Vedotin-Pembrolizumab combination in reshaping bladder cancer treatment. The interview is a key discussion with Dr. Tim Powles, MD, exploring the future of bladder cancer care.